Piper cubeba targets multiple aspects of the androgen-signalling pathway. A potential phytotherapy against prostate cancer growth?

Planta Medica

Volumn 74, Issue 1, 2008, Pages 33-38

  Yam, Jianying ^a,b   Kreuter, Matthias ^b   Drewe, Juergen ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b VitaPlant AG   (Switzerland)

Author keywords

5 reductase II; Androgen receptor; Apoptosis; LNCaP cells; Piper cubeba (L.); Piperaceae; PSA

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; P 9605; PIPER CUBEBA EXTRACT; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA SYNTHESIS; DRUG INHIBITION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; PHYTOTHERAPY; PIPERACEAE; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGNANS; MALE; PHYTOTHERAPY; PIPER; PLANT EXTRACTS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SEEDS; SIGNAL TRANSDUCTION;

PIPER CUBEBA; PIPERACEAE;

EID: 39149084965     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993758     Document Type: Article

References (22)

1. Coffey DS, Isaacs JT. Control of prostate growth. Urology 1981; 17: 17-24
2. Michael K Brawer M. Hormonal therapy for prostate cancer. Rev Urol 2006; 8 (Suppl 2): 35-47
3. Feldman BJ. The developement of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-5
4. Hsu JC, Zhang J, Dev A, Wing A, Bjeldanes LF, Firestone GL. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells. Carcinogenesis 2005; 26: 1896-904
5. Bemis DL, Capodice JL, Desai M, Buttyan R, Katz AE. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin Cancer Res 2004; 10: 5282-92
6. Medicinal Herb Index Indonesia, 2nd edition. Jakarta: PT Eisai Indonesia; 1995: 21
7. Usia T, Watabe T, Kadota S, Tezuka Y. Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod 2005; 68: 64-8
8. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride study group. N Engl J Med 1992; 327: 1185-91
9. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21: 383-91
10. Le HT, Schaldach CM, Firestone GL, Bjeldanes LF. Plant derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 2003; 278: 21136-45
11. Sciarra A, Cardi A, Di Silverio F. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urol Int 2004; 72: 91-8
12. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Rel Cancer 2003; 10: 209-16
13. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Mol Oncol 2001; 7: 1273-81
14. Edwards J, Bartlett JMS. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 2005; 95: 1320-6
15. Edwards J, Bartlett JMS. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 2005; 95: 1327-35
16. Johnstone R, Ruefli A, Lowe S. Apoptosis a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-64
17. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-18
18. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23
19. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995; 136: 796-803
20. Cleutjens KBJM, van Eekelen CCEM, van der Korput HAGM, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996; 271: 6379-88
21. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994; 142: 407-15
22. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1: 1089-94